Everything below concerns c-Met signaling. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-24. Numbers and descriptions here follow the published literature rather than marketing material.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Common recreational drugs include caffeine, commonly found in coffee, tea, soft drinks, and chocolate; alcohol, commonly found in beer, wine, cocktails, and distilled spirits; nicotine, commonly found in tobacco, tobacco-based products, and electronic cigarettes; cannabis and hashish (with legality of possession varying inter/intra-nationally); and the controlled substances listed as controlled drugs in the Single Convention on Narcotic Drugs (1961) and the Convention on Psychotropic Substances (1971) of the United Nations (UN). Since the early 2000s, the European Union (EU) has developed several comprehensive and multidisciplinary strategies as part of its drug policy in order to prevent the diffusion of recreational drug use and abuse among the European population and raise public awareness on the adverse effects of drugs among all member states of the European Union, as well as conjoined efforts with European law enforcement agencies, such as Europol and EMCDDA, in order to counter organized crime and illegal drug trade in Europe.
==== BASIC ==== The BASIC assembly strategy was developed in 2015 and sought to address the limitations of previous assembly techniques, incorporating six key concepts from them: standard reusable parts; single-tier format (all parts are in the same format and are assembled using the same process); idempotent cloning; parallel (multipart) DNA assembly; size independence; automatability. DNA parts and linker design The DNA parts are designed and cloned into storage plasmids, with the part flanked by an integrated prefix (iP) and an integrated suffix (iS) sequence. The iP and iS sequences contain inward facing BsaI restriction sites, which contain overhangs complementary to the BASIC linkers. Like in MODAL, the 7 standard linkers used in BASIC were designed with the R2oDNA Designer software, and screened to ensure that they do not contain sequences with homology to chassis genomes, and that they do not contain unwanted sequences like secondary structure sequences, restriction sites or ribosomal binding sites. Each linker sequence is split into two halves, each with a 4 bp overhang complementary to the BsaI restriction site, a 12 bp double stranded sequence and sharing a 21 bp overlap sequence with the other half. The half that is will bind to the upstream DNA part is known as the suffix linker part (e.g. L1S) and the half that binds to the downstream part is known as the prefix linker part (e.g. L1P). These linkers form the basis of assembling the DNA parts together.
All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for opioid use disorder in their practice if permitted by applicable state law. The Substance Abuse and Mental Health Services Administration encourages practitioners to treat patients within their practices who require treatment for a substance use disorder. Because it may now be prescribed much more readily out of an office setting (as opposed to methadone, which requires specialized centers), buprenorphine/naloxone allows people more access to this medication and more freedom of administration. It also thus comes with more risks in this vulnerable population. Buprenorphine/naloxone may be recommended for socially stable people who use opioids who cannot retrieve medications from a center daily, who have another condition requiring regular primary care visits, or who have jobs or daily lives that require they maintain all their faculties and cannot take a sedating medication. Buprenorphine/naloxone is also recommended over methadone for people at high risk of methadone toxicity, such as the elderly, those taking high doses of benzodiazepines or other sedating substances, concomitant alcohol use disorder, those with a lower level of opioid tolerance, and those at high risk of prolonged QT interval. It is also helpful to use the medication in combination with psychosocial support and counseling.
Cmin is a term used in pharmacokinetics for the minimum blood plasma concentration reached by a drug during a dosing interval, which is the time interval between administration of two doses. This definition is slightly different from Ctrough, the concentration immediately prior to administration of the next dose. Cmin is the opposite of Cmax, the maximum concentration that the drug reaches. Cmin must be above certain thresholds, such as the minimum inhibitory concentration (MIC), to achieve a therapeutic effect. In most cases Cmin is directly measurable. At steady state the minimum plasma concentration can also be calculated using the following equation:
== Bound-state β− decay == A very small minority of free neutron decays (about four per million) are "two-body decays": the proton, electron and antineutrino are produced, but the electron fails to gain the 13.6 eV energy necessary to escape the proton, and therefore simply remains bound to it, as a neutral hydrogen atom. In this type of beta decay, in essence all of the neutron decay energy is carried off by the antineutrino. For fully ionized atoms (bare nuclei), it is possible in likewise manner for electrons to fail to escape the atom, and to be emitted from the nucleus into low-lying atomic bound states (orbitals). This can in theory occur for neutral atoms, as a new bound state is always opened by the decay, but rarely is appreciable. Bound-state β− decays were predicted by Daudel, Jean, and Lecoin in 1947, and the phenomenon in fully ionized atoms was first observed for 163Dy66+ in 1992 by Jung et al. of the Darmstadt Heavy-Ion Research Center. Though neutral 163Dy is stable, fully ionized 163Dy66+ undergoes β− decay into the K and L shells with a half-life of 47 days. The resulting nucleus – 163Ho66+ – is stable only in this almost fully ionized state and will decay via electron capture back into 163Dy in the neutral state. Likewise, while being stable in the neutral state, the fully ionized 205Tl81+ undergoes bound-state β− decay to 205Pb81+ with a half-life of 291+33−27 days. The half-lives of neutral 163Ho and 205Pb are respectively 4570 years and 1.70×107 years. The Q-value of bound-state beta decay of a highly-ionized atom,
Sources: en.wikipedia.org
Vertebral artery dissection (VAD) is a flap-like tear of the inner lining of the vertebral artery, which is located in the neck and supplies blood to the brain. After the tear, blood enters the arterial wall and forms a blood clot, thickening the artery wall and often impeding blood flow. The symptoms of vertebral artery dissection include head and neck pain and intermittent or permanent stroke symptoms such as difficulty speaking, impaired coordination, and visual loss. It is usually diagnosed with a contrast-enhanced CT or MRI scan. Vertebral dissection may occur after physical trauma to the neck, such as a blunt injury (e.g. traffic collision) or strangulation, or after sudden neck movements (e.g. coughing), but may also happen spontaneously. 1–4% of spontaneous cases have a clear underlying connective tissue disorder affecting the blood vessels. Treatment is usually with either antiplatelet drugs such as aspirin or with anticoagulants such as heparin or warfarin. Vertebral artery dissection is less common than carotid artery dissection (dissection of the large arteries in the front of the neck). The two conditions together account for 10–25% of non-hemorrhagic strokes in young and middle-aged people. Over 75% recover completely or with minimal impact on functioning, with the remainder having more severe disability and a very small proportion (about 2%) dying from complications. It was first described in the 1970s by the Canadian neurologist C. Miller Fisher.
Liver or kidney failure – Lorazepam may be safer than most benzodiazepines in people with impaired liver function. Like oxazepam, it does not require liver oxidation, but only liver glucuronidation into lorazepam-glucuronide. Therefore, impaired liver function is unlikely to result in lorazepam accumulation to an extent causing adverse reactions. Similarly kidney disease has minimal effects on lorazepam levels. Drug and alcohol dependence – The risk of abuse of lorazepam is increased in dependent people. Comorbid psychiatric disorders also increase the risk of dependence and paradoxical adverse effects.
== Uses of bases == Sodium hydroxide is used in the manufacture of soap, paper, and the synthetic fiber rayon. Calcium hydroxide (slaked lime) is used in the manufacture of bleaching powder. Calcium hydroxide is also used to clean the sulfur dioxide, which is caused by the exhaust, that is found in power plants and factories. Magnesium hydroxide is used as an 'antacid' to neutralize excess acid in the stomach and cure indigestion. Sodium carbonate is used as washing soda and for softening hard water. Sodium bicarbonate (or sodium hydrogen carbonate) is used as baking soda in cooking food, for making baking powders, as an antacid to cure indigestion and in soda acid fire extinguisher. Ammonium hydroxide is used to remove grease stains from clothes
== Non-visa restrictions == ===Blank passport pages=== Many countries require a minimum number of blank pages to be available in the passport being presented, typically one or two pages. Endorsement pages, which often appear after the visa pages, are not counted as being valid or available.
== Structure == Hydrophobins are characterised by the presence of 8 conserved cysteine residues that form 4 disulphide bonds. They are able to reverse the wettability of surfaces by spontaneous self-assembly of the monomeric proteins into amphipathic monolayers at hydrophobic:hydrophilic surfaces. Despite this common feature, hydrophobins are subdivided into two classes based on differences on their monomeric structure, such as the spacing between the cysteine residues, and based on the different physicochemical properties of the amphipathic monolayers they form. Extensive structural analyses of individual hydrophobins from the two classes have elucidated that the morphological and physical differences between the class I and class II polymer forms are the results of significant structural differences at the monomer-assembly level.
Sources: en.wikipedia.org
=== Lobbying the FDA === In 2011, the FDA made it a priority to clarify the requirements for approval for such a closed-loop monitoring and drug delivery device for T1D, and announced it was preparing draft guidelines. Breakthrough T1D launched a campaign to influence those guidelines to be lenient. After the first closed-loop device was approved in 2016, Breakthrough T1D lobbied insurance companies to cover it. The campaign also put resources into educating people with diabetes on how to navigate health insurance in the United States, and into lobbying Congress to continue funding diabetes research through the NIH. The FDA lobbying campaign was part of a gradual realignment of the organization to focus on issues other than helping find a cure for type 1 diabetes, but to help treat and manage the disease. This broadened scope meant that the organization increasingly directed its funds to education and advocacy, along with research funding. This included lobbying insurance companies to pay for CGM devices, educating patients on how to advocate for themselves, and lobbying Congress for more NIH funding.
== Taxonomy == This species was originally noted and named in 1753 by Carl Linnaeus as Agaricus campestris. It was placed in the genus Psalliota by Lucien Quelet in 1872. Some variants have been isolated over the years, a few of which now have species status, for example, Agaricus bernardii Quel. (1878), Agaricus bisporus (J.E. Lange) Imbach (1946), Agaricus bitorquis (Quel.) Sacc. (1887), Agaricus cappellianus Hlavacek (1987), and Agaricus silvicola (Vittad.) Peck (1872). Some were so similar they did not warrant even varietal status, while others have retained it. Agaricus campestris var. equestris (F.H.Moller) Pilat (1951) is still valid. A. campestris var. isabellinus (F.H.Moller) Pilat (1951), and A. campestris var. radicatus, are possibly still valid too. The Latin specific epithet campestris means "of the fields". Common names given to the fungus include "meadow mushroom", "pink bottom", and "field mushroom". An analysis of ribosomal DNA of a limited number of members of the genus showed A. campestris to be an early offshoot in the genus and sister taxon to A. cupreobrunneus.
Blood is filtered at the kidneys and liver. The body consists of a number of body cavities, separated areas which house different organ systems. The brain and central nervous system reside in an area protected from the rest of the body by the blood brain barrier. The lungs sit in the pleural cavity. The intestines, liver, and spleen sit in the abdominal cavity. Height, weight, shape and other body proportions vary individually and with age and sex. Body shape is influenced by the distribution of bones, muscle and fat tissue.
=== VIP receptors === VIP acts on two receptors - VPAC1 and VPAC2, which are class B of G-protein-coupled receptors (GPCRs).VPAC1 is mainly present in the lung and T-lymphocytes, whereas VPAC2 is mainly seen in the smooth muscle, mast cells and the basal parts of the lung mucosa.
Relatedly, muscimol, similarly to gaboxadol, has been described as being highly though incompletely selective for these GABAA receptors. In contrast, benzodiazepines and Z-drugs do not activate δ subunit-containing GABAA receptors. On the other hand, alcohol is known to selectively potentiate δ subunit-containing extrasynaptic GABAA receptors analogously to muscimol. While muscimol is often thought of as a selective GABAA agonist with exceptionally high affinity to δ subunit-containing GABAA receptors, it is also a potent partial agonist of the GABAA-ρ receptor, and so its range of effects results from a combined action on more than one GABAA receptor subtype. In fact, it is more potent as a partial agonist of the GABAA-ρ receptor than as a GABAA receptor agonist. Muscimol has been said to be inactive at the GABAB receptor. However, a subsequent study reported that muscimol may have GABAB receptor-mediated inhibitory activity, although more research is needed to further characterize this activity. Muscimol is inactive in terms of affecting GABA transaminase (GABA-T). There is little evidence that muscimol interacts with other biological targets besides the GABA receptors and the GABA transporters. Muscimol shows a very steep dose–response curve in rodents. It produces effects in rodents including central depression, hypolocomotion, catalepsy, sedation, ataxia, analgesia, anxiolysis, anticonvulsant effects, neuroprotective effects, and anesthesia, among other effects.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.